Working at the intersection of innovation, technology and product development, I manage the external innovation portfolio for antibody discovery and protein engineering in R&D. This includes identifying novel technologies for our core therapeutic areas, as well as emerging platforms like cell therapy, peptide delivery, oral biologics and adeno associated virus (AAV), and building next generation antibody conjugate technologies for tissue targeting and to prevent off target toxicity.
My role sees me liaise closely with our therapeutic area heads and business development colleagues to lead and execute the evaluation of novel technologies through data-driven feasibility studies. I also design and run open innovation challenges and scientific advisory boards to ensure we address internal gaps and identify the most exciting technologies and collaborators.
With over 20 years of experience in pharma/biotech, I started my career as a research scientist in academia after gaining my PhD from Purdue University in Chemistry and Materials Science & Engineering.
Over my career, I have led teams to secure a number of novel drug delivery approvals such as an injectable biologic drug-device combination product, an active transdermal patch and a dry powder inhalation device. I also have more than 25 peer reviewed publications and 2 book chapters, as well as several granted patents.
2017: Global excellence award for the best patent
2013: Exceptional Team Performance award
Developed and led nanoparticle-based drug delivery strategies for immune targeting and novel nano antibody drug conjugates for targeted delivery, and provided leadership and successfully executed several digital health clinical pilots using connected devices and sensors
Invited speaker at the Translational Oncology Program at Stanford (TOPS)
Led a team that secured approval for an injectable biologic drug-device combination product and developed disruptive drug delivery approaches for the portfolio
Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P, Subramony JA. J Controlled Release, 2018. 272; 159–168.
Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.
Chen F, et al. Nature Comms 2018. 9:4141
Oral peptide delivery: Translational challenges due to physiological effects.
Tyagi P, Pechenov S, Subramony JA. J Controlled Release. 2018. 287; 167–176
Improving Drug-Like Properties of Insulin and GLP-1 via Molecule Design and Formulation and Improving Diabetes Management with Device & Drug Delivery.
Pechenov S, Bhattacharjee H, Yin D, Mittal S, Subramony JA. Adv Drug Deliv Rev. 2017.
Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.
Fakhari A, Subramony JA. J Controlled Release 2015. 220; 465–475
Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large Volume Protein Delivery.
Doughty DV, Clawson CZ, Lambert W, Subramony JA. J Pharm Sci. 2016 105(7):2105-13